Methadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY)

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorAlexandre P. Joosten

About this trial

Postoperative pain control remains suboptimal for a large proportion of surgical patients and is frequently associated with slower recovery and higher reliance on opioids after surgery. Current intraoperative analgesic approaches predominantly use short-acting opioids, whose rapid pharmacokinetics can lead to variable drug exposure and inconsistent control of nociceptive stimuli.

Methadone has a different pharmacologic profile, combining prolonged μ-opioid receptor activity with N-methyl-D-aspartate receptor antagonism, allowing sustained analgesia following a single intraoperative administration and potentially enhancing postoperative recovery.

The MELODY trial is a multicentre, randomized, patient-blinded clinical study designed to compare a single intravenous dose of methadone given at induction with conventional short-acting opioid-based anesthesia in adults undergoing intermediate-risk noncardiac surgery. The primary aim is to evaluate whether this strategy leads to improved quality of recovery on the first postoperative day.

Eligibility criteria

Qualifiers

Age ≥18 years

Elective intermediate-risk noncardiac surgery under general anesthesia

ASA physical status I-III

Expected hospital stay ≥24 hours

Disqualifiers

Severe hepatic dysfunction (Child-Pugh C)

Severe renal impairment (eGFR <30 mL/min/1.73 m²)

Known allergy to methadone or opioids

Pregnancy or breastfeeding

Trial design

Treatments tested in this trial

  • Intravenous Methadone
  • Short-acting Opioids Intraoperative analgesia

Treatment groups

400 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Alexandre P. Joosten

Lead sponsor

University of California, Los Angeles

Sponsor institution